Navigation Links
Æterna Zentaris Receives NASDAQ Notification Related to Minimum Bid Price
Date:1/23/2010

QUEBEC CITY, Jan. 22 /PRNewswire-FirstCall/ - Æterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule"). In accordance with NASDAQ Listing Rule 5810(C)(3)(a), Æterna Zentaris is provided a grace period of 180 calendar days, or until July 20, 2010, to regain compliance with this requirement. The notice has no effect on the listing of Æterna Zentaris' common shares at this time, and its common shares will continue to trade on the NASDAQ under the symbol "AEZS", as well as on the Toronto Stock Exchange under the symbol "AEZ".

Æterna Zentaris can regain compliance with the Rule if the bid price of its common shares closes at US$1.00 or higher for a minimum of ten consecutive business days during the grace period, although NASDAQ may, in its discretion, require the Company to maintain a minimum closing bid price of at least US$1.00 per share for a period in excess of ten consecutive business days before determining that Æterna Zentaris has demonstrated the ability to maintain long-term compliance.

If the Company is unsuccessful in meeting the minimum bid requirement by July 20, 2010, Nasdaq will provide notice to Æterna Zentari
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 Deep Research Report ... professional and in-depth research report on the ... Seaweed Fertilizer information, including Seaweed Fertilizer definition, ... well as industry overview. This research covers ... as well as global industry analysis covering ...
(Date:8/21/2014)... The College of New Rochelle announced ... the Mid-Hudson Region to be designated as a START-UP ... from qualified “high-technology” businesses that align with the College’s ... have been selected for the START-UP NY program and ... stimulate economic development in New York by growing business ...
(Date:8/21/2014)... -- China Cord Blood Corporation (NYSE: CO ) ... results for the first quarter of fiscal year 2015 ... the US.  The Company will host ... August 29, 2014 to discuss its financial performance and ... followed by a question and answer session.  Interested parties ...
(Date:8/21/2014)... August 21, 2014 Gallus ... contract development and manufacturing organization (CMO) announced today ... Inc., an oncology company focused on the development ... to manufacture the anti-prostate specific membrane antigen (PSMA) ... candidate. Under the agreement the antibody will ...
Breaking Biology Technology:Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3
... Kiadis,Pharma announced today that the U.S. Food ... Rhitol(TM) Orphan Drug Designation for the treatment ... complication of allogeneic,bone marrow transplantation is highly ... patient is unresponsive to steroid treatment.,Rhitol(TM) has ...
... PHILADELPHIA, Pennsylvania, April 15, THIS ANNOUNCEMENT IS AN ... SUBSCRIBE FOR OR PURCHASE ANY,SECURITIES REFERRED TO IN ... BE CONTAINED IN THE PROSPECTUS EXPECTED TO BE ... SCHEME. THE PROSPECTUS WILL,BE PUBLISHED AND MADE AVAILABLE ...
... ... Session -, SAN FRANCISCO and ... that data from an ongoing,Phase 1-2 clinical trial showed that the Company,s ... (PSA), a marker of tumor growth, in the lowest expanded dose group,tested ...
Cached Biology Technology:Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA 2Shire to Introduce a New UK Listed Holding Company 2Shire to Introduce a New UK Listed Holding Company 3Shire to Introduce a New UK Listed Holding Company 4Shire to Introduce a New UK Listed Holding Company 5Shire to Introduce a New UK Listed Holding Company 6Shire to Introduce a New UK Listed Holding Company 7Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients 2Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients 3
(Date:8/21/2014)... the journal Carcinogenesis by researchers at the ... protein adenomatous polyposis coli (APC) in suppressing colorectal cancer ... U.S. , Lead author Kristi Neufeld, associate professor in ... Cancer Biology program at the KU Cancer Center, has ... understand the various activities of APC, a protein whose ...
(Date:8/21/2014)... A team of researchers at Louisiana Tech ... using affordable, consumer-grade 3D printers and materials ... contain antibacterial and chemotherapeutic compounds for targeted ... doctoral students and research faculty from Louisiana ... collaborated to create filament extruders that can ...
(Date:8/21/2014)... State University have developed a novel and versatile modeling ... for creating new materials as well as for studying ... allows us to model much larger and more complex ... says Nan Li, lead author of a paper on ... Department of Materials Science and Engineering. "This is a ...
Breaking Biology News(10 mins):Research offers insight into cellular biology of colorectal cancer 2Research offers insight into cellular biology of colorectal cancer 3Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3Researchers develop models to study polyelectrolytes, including DNA and RNA 2
... have hypothesized that the fetus can be exposed to ... the mother has been exposed, and this may have ... eczema and asthma) later in an infant’s life. However ... to detect antigen-specific T cells in cord blood. Recently, ...
... discovered 24 species believed to be new to science, ... amphibians, fish and insects. , Presented in a report ... led by Conservation International’s Rapid Assessment Program (RAP) and ... exploring unknown regions such as Suriname’s rainforest to assess ...
... dormant bacterial spores, researchers have revealed through atomic force ... cell wall that accompany the transformation from a spore ... Bacillus (rod-shaped bacteria) cells initiate a series of genetic, ... of metabolically dormant spores. They can remain dormant for ...
Cached Biology News:Researchers find 24 species believed new to science in Suriname rainforest 2Researchers track how spores break out of dormant state 2
... ELx50 is a fast and versatile automated ... our patented Dual-ActionTM 16-channel manifold. This breakthrough ... dispense and aspiration manifolds for overfill washing ... 384-well formats. The problem of fitting dispense ...
... The HybArray 12™ is an automated ... microarrays. The system automates both the hybridization ... onto glass slides. A single instrument can ... time in pairs and has multi-protocol software, ...
... S&S Custom Array Service enables scientists who have ... to have FAST Slides printed with proteins from ... Processing of the arrays is performed by the ... S&S to discuss your needs with an expert ...
Acetylcholinesterase (human brain, AChE)...
Biology Products: